Skip to main content

Table 3 Overview of results on ratios of odds ratios for assessment of low disease activity and remission using the DAS 28, SDAI, CDAI and the Boolean approach (remission only), active-controlled studies

From: A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis

Treatment comparison

Low disease activity, ROR (p value)

Remission, ROR (p value)

Number of studies

Number of patients

DAS 28 versus CDAI

DAS 28 versus SDAI

SDAI versus CDAI

Number of studies

Number of patients

DAS 28 versus CDAI

DAS 28 versus SDAI

SDAI versus CDAI

DAS 28 versus Boolean approach

SDAI versus Boolean approach

CDAI versus Boolean approach

IL-6 inhibitor versus TNFα inhibitor

Sarilumab versus adalimumab; monotherapy

1*

169

2.07 (0.009)

2.14 (0.005)

0.97 (0.687)

1*

169

1.62 (0.478)

1.42 (0.586)

1.14 (0.641)

2.69 (0.187)

1.89 (0.314)

1.66 (0.439)

Tocilizumab versus adalimumab; monotherapy

1*

131

1.83 (0.016)

1.82 (0.013)

1.00 (0.974)

1*

131

3.45 (0.009)

2.27 (0.080)

1.54 (0.020)

2.27 (0.117)

1.00 (1.000)

0.65 (0.298)

Tocilizumab + MTX versus adalimumab + MTX

1†

69

2.65 (0.031)

1.28 (0.570)

2.08 (< 0.001)

1†

69

0.93 (0.908)

0.43 (0.318)

2.13 (0.129)

0.89 (0.872)

2.08 (0.269)

0.97 (0,962)

TNFα inhibitor versus TNFα inhibitor

Certolizumab pegol + MTX versus adalimumab + MTX

1‡

836

0.96 (0.680)

1.04 (0.679)

0.93 (0.016)

1‡

836

1.00 (0.982)

1.06 (0.696)

0.94 (0.360)

1.19 (0.321)

1.12 (0.406)

1.19 (0.229)

JAK inhibitor versus TNFα inhibitor

Baricitinib + MTX versus adalimumab + MTX

1‡

817

1.00 (0.987)

0.99 (0.917)

1.01 (0.800)

1‡

817

0.79 (0.147)

0.76 (0.073)

1.04 (0.538)

0.83 (0.311)

1.09 (0.582)

1.04 (0.778)

Filgotinib + MTX versus adalimumab + MTX

1‡

800

1.06 (0.588)

0.98 (0.878)

1.07 (0.042)

1‡

800

0.96 (0.796)

1.02 (0.887)

0.94 (0.310)

0.96 (0.789)

0.94 (0.627)

0.99 (0.960)

Tofacitinib + MTX versus adalimumab + MTX

2§

1152

0.85 (0.088)

0.87 (0.115)

0.98 (0.397)

2§

1152

0.74 (0.020)

0.82 (0.105)

0.90 (0.091)

0.77 (0.086)

0.94 (0.615)

1.05 (0.727)

Upadacitinib + MTX versus adalimumab + MTX

1‡

978

1.07 (0.476)

1.04 (0.634)

1.02 (0.462)

1‡

978

1.00 (0.999)

0.93 (0.660)

1.07 (0.293)

0.93 (0.700)

0.99 (0.971)

0.93 (0.643)

JAK inhibitor versus T-cell activation inhibitor

Upadacitinib + MTX versus abatacept + MTX

1†

438

1.46 (0.032)

1.38 (0.049)

1.06 (0.131)

1†

438

1.37 (0.082)

1.20 (0.244)

1.14 (0.193)

1.38 (0.101)

1.16 (0.349)

1.01 (0.951)

T-cell activation inhibitor versus TNFα inhibitor

Abatacept + MTX versus adalimumab + MTX

1‡

606

0.96 (0.721)

0.98 (0.860)

0.98 (0.583)

1‡

606

0.89 (0.539)

0.94 (0.753)

0.94 (0.453)

1.06 (0.811)

1.13 (0.555)

1.19 (0.386)

  1. The thresholds used for the assessments were: DAS 28 < 3.2, SDAI ≤ 11 and CDAI ≤ 10 for low disease activity, DAS 28 < 2.6, SDAI ≤ 3.3, CDAI ≤ 2.8 and Boolean approach (≤ 1 swollen joint, ≤ 1 tender joint, C-reactive protein ≤ 1 mg/dl and global assessment of disease activity by the patient ≤ 1 on a scale from 0 to 10) for remission
  2. Statistically significant RORs are shown in bold font
  3. 95% CIs are shown in Additional file 1: Tables 3 and 4
  4. CDAI clinical disease activity index; DAS 28 disease activity score 28; MTX methotrexate; RORs ratio of odds ratios, SDAI simplified disease activity index
  5. *Includes only studies on patients with MTX intolerance
  6. † Includes only studies on patients after biologic failure
  7. ‡ Includes only studies on patients after MTX failure
  8. §Includes only studies on patients after MTX or biologic failure
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us